First AD

Second AD

Impact and Positioning of Tumor Agnostic Approvals

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

My Treatment Approach: Targeting Genetic Alterations in Tumors: Clinical Scenarios and Precision Oncology Approaches

Insights

The panel discusses the impact of tumor agnostic approvals like BRAF/MEK inhibitors on the treatment landscape, unmet needs address and sequencing therapies like RET inhibitors in cancers like pancreatic cancer. 

Impact and Positioning of Tumor Agnostic Approvals  

Overview of Tumor agnostic Treatment: Considerations for NGS Testing in Solid Tumors 

Targeting RET Fusion in Brain Tumor

BRAF V600E Mutant Ganglioglioma 

Challenges in Adopting Targeted Therapies for BRAF Alterations

Efficacy and Safety of Tumor Agnostic Therapies  

PRKAR1A-RET Fusion in Pancreatic Cancer: Unlocking New Therapeutic Frontiers 

Future Outlook for RET Fusion-Targeted Therapies 